title: [Liraglutide and glimepiride on glycaemic control in type 2 diabetes in the Mexican cohort (LEAD 3)].
abstract: OBJECTIVE
  To compare the efficacy of liraglutide monotherapy with glimepiride monotherapy in subjects with DM2 inadequately controlled by previous treatment of diet/exercise or oral antidiabetic drug.
  
  
  METHODS
  A 52-week, double-blinded, active-controlled, parallel-group, multi-centre, prospective trial, involving 746 subjects was conducted in the USA and Mexico. In Mexico, 171 subjects were rando-mised (1:1:1) to once daily liraglutide (either 1.2, or 1.8 mg/day injected subcutaneously) or glimepiride (8 mg/day orally).
  
  
  RESULTS
  Hb1Ac reduced by 0.64%, 1.31% and 0.30% with glimepiride, liraglutide 1.8 mg and 1.2 mg, respectively. Body weight decreased with both liraglutide doses while a weight gain of 0.94 kg was observed with glimepiride. FPG reduced by 27.9 mg/dL with liraglutide 1.8 mg, whereas a FPG increase of 9.54 mg/dL was shown with glimepiride. No major hypoglycaemic episodes were reported in this trial.
  
  
  CONCLUSIONS
  in Mexican subjects with DM2, liraglutide monotherapy can provide greater reduction in HbA1c, weight loss and lower risk of hypoglycaemia in comparison with glimepiride.
authors.affiliation: Servicio de Endocrinología, Hospital Universitario de Monterrey "Dr. José Eleuterio González," Monterrey, Nuevo León, México. pedroalbertogh@yahoo.com
authors.forename: Pedro
authors.initials: P
authors.lastname: García-Hernández
authors.forename: María del Rosario
authors.initials: Mdel R
authors.lastname: Arechavaleta-Granell
authors.forename: Jorge
authors.initials: J
authors.lastname: Yamamoto
authors.forename: Ali
authors.initials: A
authors.lastname: Falahati
authors.forename: Guillermo
authors.initials: G
authors.lastname: González-Gálvez
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001786:Blood Glucose; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069450:Liraglutide; D008297:Male; D008800:Mexico; D008875:Middle Aged; D011446:Prospective Studies; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; C057619:glimepiride; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1